Gossamer Bio (GOSS) announced enrollment completion for the ongoing, global registrational Phase 3 PROSERA study evaluating seralutinib in Functional Class II and III PAH patients. Gossamer Bio and the Chiesi Group are jointly developing seralutinib under a global collaboration agreement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GOSS:
- Gossamer Bio’s Promising Clinical Advances and Strong Financial Position Justify Buy Rating
- Optimistic Growth Prospects for Gossamer Bio Amid Strategic Advances and Study Alignments
- Gossamer Bio’s Earnings Call: Mixed Sentiments and Strategic Moves
- Gossamer Bio Reports Q1 2025 Results and Study Updates
- Gossamer Bio reports Q1 EPS (16c), consensus (19c)